Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
Ron Epelbaum(University of Bern), Ravit Geva(Tel Aviv Sourasky Medical Center), Eliahu Gez(Rambam Health Care Campus), Ronen Brenner(Tel Aviv University), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Ofer Purim(Tel Aviv University), Mark Temper(Hadassah Medical Center), Baruch Brenner(Rabin Medical Center), Abed Agbarya(Technion – Israel Institute of Technology), Ella Tepper(Assuta Medical Center), Einat Shacham‐Shmueli(Sheba Medical Center), Talia Golan(Sheba Medical Center), Andreas Voß(Enzo Life Sciences (Switzerland)), Ayala Hubert(Sheba Medical Center), Addie Dvir(Teva Pharmaceuticals (Israel)), Salomon M. Stemmer(Tel Aviv University), Baruch Klein(Tel Aviv University), Kenneth Russell(Siemens Healthcare (United States))
Cited by 10
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Duration of Androgen Suppression in the Treatment of Prostate Cancer
|New England Journal of Medicine|2009|966